FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like FDA Approves Monthly Buprenorphine MAT for Opioid Use Disorder December 1, 2017 FDA Guidance Steps Up Push to Speed Generics to Market October 2, 2017 Commissioner Califf Calls for Better Use of Health Data April 5, 2022